Oncology

Your Article Summary

See Latest Articles

S-1 monotherapy in patients with advanced biliary tract cancer
Oncology (Karger), 06/30/09

Sasaki T et al. - In a trial to evaluate the efficacy and safety of single-agent S-1 in pts with advanced biliary tract cancer, it was reported that S-1 monotherapy is a feasible and moderately efficacious treatment for advanced biliary tract cancer, as a first- or second-line chemotherapy regimen.

• S-1 was administered orally at a dose of 80 mg/m2 for 28 days, followed by 14 days of rest (1 cycle).
• Treatment was repeated until disease progression, unacceptable toxicity, or pt refusal.

• 45 pts were enrolled; among these, 29 pts received S-1 as first-line chemotherapy and 16 pts received S-1 as second-line chemotherapy.
• Response rates for first- and second-line chemotherapy were 17.2 and 18.8%, respectively.
• Median times to progression for first- and second-line chemotherapy groups were 4.2 and 5.5 mos, respectively.
• Median overall survival and 1-yr survival rate for each group were 8.7 and 8.0 mos and 42.2 and 38.2%, respectively.
• Only the first-line chemotherapy group experienced grade 3/4 toxicities, including leukopenia (6.9%), neutropenia (10.3%), anemia (6.9%), thrombocytopenia (10.3%) and total bilirubin elevation (3.4%).

Related Articles

See all related articles

Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
Annals of Oncology, 10/19/09    Relevance Score: 45%

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study : The Lancet Oncology
The Lancet Oncology - Online First, 10/09/09    Relevance Score: 44%

Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study)
Annals of Oncology, 11/06/09    Relevance Score: 43%

A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity
European Journal of Surgical Oncology, 10/28/09    Relevance Score: 40%

Completely Displaced S-1/S-2 Growth Plate Fracture in an Adolescent: Case Report and Review of Literature
Journal of Orthopaedic Trauma, 10/28/09    Relevance Score: 40%

Today in GI Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Loss of imprinting of the insulin-like growth factor II (IGF2) gene in esophageal normal and adenocarcinoma tissues
Carcinogenesis, 12/15/09

Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44
Carcinogenesis, 12/15/09

Toxicity against gastric cancer cells by combined treatment with 5-fluorouracil and mitomycin c: Implication in oxidative stress
Cancer Chemotherapy and Pharmacology, 12/15/09

 See all of GI Oncology

Today in Hepatobiliary/Pancreas...keeping you current

Receive free subspecialty "5-minute updates" via email

An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma
Carcinogenesis, 12/15/09

Are patients of low socioeconomic status receiving suboptimal management for pancreatic adenocarcinoma
Cancer, 12/15/09

MicroRNA in pancreatic cancer: Pathological, diagnostic and therapeutic implications
Cancer Letters, 12/15/09

 See all of Hepatobiliary/Pancreas

Today in Pharmacology/Therapy...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
Journal of Neuro-Oncology, 12/15/09

Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines
Cancer Chemotherapy and Pharmacology, 12/15/09

Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol
Cancer, 12/15/09

 See all of Pharmacology/Therapy